linjc16/ctgov huggingface dataset:
Sparing Diaphragm; ISO Block Versus Low Volume Scalene Block

Study Overview
=================
Brief Summary
-----------------
For shoulder analgesia, both ISO block and low volume scalene (LVS) block (using 5 ml of local anesthetics) are suggested to have a low incidence of hemi-diaphragmatic pariesis (HDP). The aim of this study was to compare the incidence of HDP and the analgesic efficacy of the LVS block versus ISO block.

Official Title
-----------------
Shoulder Analgesia Sparing Diaphragm; ISO Block Versus Low Volume Scalene Block. A Randomized Controlled Double Blind Study

Conditions
-----------------
Shoulder Arthropathy Associated With Other Conditions

Intervention / Treatment
-----------------
* Procedure: scalene block
* Procedure: ISO block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who were scheduled for arthroscopic shoulder surgery Exclusion Criteria: aged <18y BMI >35, ASA greater >III, an infection at the injection site has a contraindication for laryngeal mask or the medications used in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: LVS group<br>interscalene injection | Procedure: scalene block<br>* scalene block using 5ml of ropivacaine<br>|
| Active Comparator: ISO group<br>in this group all patients will receive ISO block. | Procedure: ISO block<br>* ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hemi-diaphragmatic pariesis | diaphragmatic caudal displacement will be measured (in cm) with real time ultrasound before the block performance and after the procedure | 2-4 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| analgesic efficacy (block success) | successful block = pain free (VAS 0) in recovery unit. VAS will be used to evaluate the pain (0 = pain free, 10= most sever pain) | 2-4 hours | 
| patient satisfaction | if the patient is satisfied with the analgesia technique or not | 24 hours | 
| duration of analgesia | duration between the block performance and the first requesting of pain killer (morphine) | 24 hours | 
| total morphine dose | the total morphine consumption within 24 hrs after the block performance | 24 hours |
Study Evaluating Venlafaxine ER in Adults With Panic Disorder

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study.

Official Title
-----------------
A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder

Conditions
-----------------
Panic Disorder

Intervention / Treatment
-----------------
* Drug: Venlafaxine ER


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A male or female outpatient Be at least 18 years of age and legal age of consent Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1 Exclusion Criteria: Treatment with venlafaxine (IR or ER) within 6 months of study day 1 Known hypersensitivity to venlafaxine (IR or ER) or related compounds History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal cell epithelioma], uncontrolled hypertension)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Venlafaxine ER|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Panic, Disorder
Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

Study Overview
=================
Brief Summary
-----------------
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

Detailed Description
-----------------
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.

Official Title
-----------------
An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide

Conditions
-----------------
Body Weight Changes

Intervention / Treatment
-----------------
* Drug: CHF Patients: ER Torsemide 40 mg
* Drug: CHF Patients: Furosemide 40 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide. Exclusion Criteria: Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CHF Patients: ER Torsemide 40 mg<br>CHF patients will be given 40 mg ER Torsemide | Drug: CHF Patients: ER Torsemide 40 mg<br>* ER Torsemide 40mg given once daily to CHF patients<br>* Other names: Demadex;|
| Active Comparator: CHF Patients: Furosemide 40 mg<br>CHF patients are on 40 mg of Furosemide | Drug: CHF Patients: Furosemide 40 mg<br>* Stable CHF patients taking twice-daily 40 mg Furosemide<br>* Other names: Lasix;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in 24-hour sodium excretion compared to baseline | the difference in 24 hour sodium excretion between ER Torsemide and Furosemide | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in body weight | Body weight changes will be compared between the two arms | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
natriuresis
RoboHear™ Device: Advanced Haptic Technology That Allows the Deaf to Understand Speech

Study Overview
=================
Brief Summary
-----------------
Pilot study to test the feasibility of translating the English language into haptics (touch sensations)

Detailed Description
-----------------
An adaptive pilot trial of RoboHear™ hardware and software to test the feasibility of learning to understand language using a haptic (touch) device installed in the stem of a pair of glasses. These tests are not meant to be exhaustive but will validate the hardware and software and provide an informal test platform for learning to 'hear' or interpret sounds and words using haptic technology.

Official Title
-----------------
RoboHear™ Device: Advanced Haptic Technology That Allows the Deaf to Understand Speech

Conditions
-----------------
Hearing Impairment, Deafness

Intervention / Treatment
-----------------
* Device: RoboHear Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants need to understand English. Participants must be able to sit at a computer for the training and evaluation session. The session may range from one hour to up to 4 hours in length (with breaks provided as needed). Exclusion Criteria: Inability to understand English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Interventional Model Description: Participants will undergo computer based testing using the device to determine the number of haptic stimuli that are correctly interpreted as phenomes.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: RoboHear Device<br>Subjects will wear the Robo-Hear device and receive haptic stimuli. They will be tested on their ability to interpret these haptic sensations as sounds and words. | Device: RoboHear Device<br>* Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Haptic Interpretation Test | A computerized test to determine accuracy of interpretation of haptic stimuli in to sounds or words. | at end of training session (1-3 hours), Day 1 |
Plyometric Training Versus Strengthening Exercise On Children With Hemiplegia

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the effect of plyometric training versus strengthening exercise on quadriceps and hamstring muscles and quality of life and selective motor control of lower limb of children with hemiplegia.

Detailed Description
-----------------
The aim of the study is to evaluate the effect of plyometric training versus strengthening exercise on quadriceps and hamstring muscles and quality of life and selective motor control of lower limb of children with hemiplegia. Hand-Held dynamometer is used to assess the muscle strength of quadriceps and hamstring Selective control assessment of lower extremity scale is used to assess selective motor control of lower limb. Peds Ql scale is used to assess quality of life of the children. The methods of assessment are valid and reliable.

Official Title
-----------------
Plyometric Training Versus Strengthening Exercise On Muscle Strength, Selective Motor Control And Quality Of Life In Children With Hemiplegia

Conditions
-----------------
Children With Hemiplegic cp, Effect of Plyometic Exercises

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Their age will be ranging from 8 to 10 years. They will be on level (1 : 1+) according to Modified Ashworth scale They will be on level I according to Gross Motor Functional Classification System They can understand and follow instructions. Exclusion Criteria: Child undergoes orthopedic surgery past one year. Visual or auditory problems that interfere with rehabilitation programs. Botox injection past 6 months. Cardiac problems or uncontrolled seizures.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle strength | Muscle strength of quadriceps and hamstrings is assessed by Hand-Held dynamometer | three months | 
| Quality of life of children | Quality of life of children (physical, psychological and social) is assessed by PedsQl scale PedsQl scale scoring from 0-100 scale The higher scores indicate better health related quality of life and lower scores indicate worse health related quality of life | three months | 
| Selective motor control of lower limb | Selective motor control of lower limb is assessed by selective control assessment of lower extremity scale The scale has 3 grades for each joint (hip, knee, ankle, sub-talar and toes) 0 point : unable point : impaired points : normal | three months |
Progressive Strength Training in Spinal Muscular Atrophy

Study Overview
=================
Brief Summary
-----------------
The proposed feasibility study is necessary to test if children and young adults will participate in and adhere to a 12-week, home-based, supervised progressive strength training exercise program and to obtain preliminary data that will subsequently allow us to determine the safety and impact of strength training in spinal muscular atrophy. Our pilot study will address 3 aims: (1) Ascertain the feasibility of, and potential barriers to, participation in and adherence to a 12-week home-based, supervised, progressive strength training exercise program in children and young adults aged 5-21 years with SMA types II and III; (2) Determine the safety and tolerability of progressive strength training in a pilot study sample of children and young adults with SMA types II and III; and (3) Determine candidate outcome measures.

Official Title
-----------------
Pilot Study of Progressive Strength Training in Spinal Muscular Atrophy

Conditions
-----------------
Muscular Atrophy, Spinal

Intervention / Treatment
-----------------
* Other: Progressive strength training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 5-21 years diagnosis of SMA type II or III at least antigravity strength in elbow flexors ability to follow commands and stay on task place of residence within a 60-minute or 60-mile drive of the University of Utah Exclusion Criteria: planned surgery or out-of-town trips during the proposed intervention period inability to travel to study center for testing neurological diagnosis other than SMA

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Spinal muscular atrophy<br>Children and adolescents with diagnosis of SMA type II or III. The intervention group (the only arm/group in this pilot study) receives a home-based, supervised, 12-week progressive strength-training program. | Other: Progressive strength training<br>* the systematic increase in resistance weights<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Strength | Primary Outcome Measure was muscle strength. Strength was measured using a fixed myometry evaluation, quantitative muscle analysis (QMA). QMA utilizes a relative fixed point for the participant to exert effort. Each muscle of interest was tested using QMA. | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spinal muscular atrophy, Neuromuscular disorder, Progressive strength training, Children
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and efficacy of Iloprost in subjects that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer TM).

Detailed Description
-----------------
This is a randomized, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) with an NYHA Class of III or IV who are receiving conventional therapy and bosentan. Subjects who fulfill the inclusion and exclusion criteria will be randomized to study drug (active or placebo) at a frequency of 6-9 inhalations per day for 12 weeks and will continue conventional therapy and bosentan. At the end of the double-blind phase study, open label Iloprost will be provided.

Official Title
-----------------
A Safety and Pilot Efficacy Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With PAH

Conditions
-----------------
Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension

Intervention / Treatment
-----------------
* Drug: Iloprost or placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of PAH due to PPH, connective tissue disease, HIV, or repaired (≥ 1 year) ASD, VSD, or PDA NYHA Functional Class III or IV On bosentan for at least 16 weeks, with the dose stable (maximum dose 125 mg BID) for at least 8 weeks Age 12-75 years, of either gender Six minute walk distance 100-425 meters at Baseline Exclusion Criteria: Any new long-term treatment for PAH added within the last 4 weeks Any therapy with a PDE (phosphodiesterase), L -arginine or a prostaglandin, concurrently, or within the last 4 weeks PAH related to chronic thromboembolic disease, portopulmonary disease, or any etiology other than PPH, connective tissue disease, HIV, or repaired ASD, VSD, or PDA

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Iloprost or placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
STEP, PAH, iloprost, inhalation, prostacyclin
Immediate Maintained Cannulation of a Newly Implanted Prosthetic Arteriovenous Access for Acute Hemodialysis

Study Overview
=================
Brief Summary
-----------------
Objectives: Examine the acute utility of immediate maintained cannulations of a newly implanted prosthetic arteriovenous access. Background: Recurrent failure of central catheterization is not uncommon. An alternative access is necessary for acute hemodialysis after the exhaustion of central veins. Methods: We constructed the access by cannulating two dialysis needle-catheters and securing them on the skin after the implantation of the graft. The access was used immediately and maintained for one week and thereafter used as a long-term access.

Conditions
-----------------
End-Stage Renal Disease, Prosthetic Arteriovenous Access

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: end-stage renal disease underwent the specific prosthetic arteriovenous access creation in our hospital from November 2003 to October 2005 Exclusion Criteria: patients' poor health as long as they did not have other options and needed an access for acute hemodialysis. Exclusions included shock, active systemic infection, and rejection by the attending nephrologists
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
underwent, specific, creation, hospital, November 2003, October 2005
Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy

Study Overview
=================
Brief Summary
-----------------
This is a prospective, randomized, open-label clinical trial to evaluate the efficacy and safety of total glucosides paeony capsules in maintaining clinical remission in patients with ankylosing spondylitis which achieved clinical remission after anti-TNF therapy. Patients will be divided into two groups randomly, one group receive non-steroid anti-inflammatory drugs(NSAID) mono-therapy and the other group receive total glucosides paeony capsules plus NSAID therapy for 24 weeks. The primary clinical endpoint is the proportion of patients which disease activity reaches relapse criteria. The investigator's hypothesis the proportion of relapse in total glucosides paeony capsules plus NSAID group would be lower than the NSAID mono-therapy group.

Conditions
-----------------
Ankylosing Spondylitis

Intervention / Treatment
-----------------
* Drug: Total Glucosides Paeony Capsules


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged from 16-65 years, sign the Informed Consent Fulfill 1984 modified NewYork classification criteria for AS Achieved clinical remission after at least 12 weeks' therapy of anti-TNF therapy Hb≥9g/dl, ALT/AST≤ 2 folds of upper level normal range, creatine≤120mol/L(≤1.4mg/dl) Commitment to contraceptive for woman Exclusion Criteria: History of psoriasis and/or inflammatory bowel diseases Receive intra-articular injection of cortisone within 3 months before enrollment History of the listed diseases: heart failure, Multiple sclerosis, severe chronic obstructive pulmonary disease, frequent infections, lymphoma or other cancers, tuberculosis Pregnant and lactating women Mentally ill, Alcoholics and drug addicts

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Total Glucosides Paeony, Capsules<br> | Drug: Total Glucosides Paeony Capsules<br>* Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks<br>|
| No Intervention: no intervention<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the proportion of patients which disease activity reaches relapse criteria |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BASDAI score comparing to baseline |  | 24 weeks | 
| BASFI score comparing to baseline |  | 24 weeks |